FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Massimo Breccia

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Physiology

Drug Resistance, Neoplasm

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Massimo Breccia; Giuliana Alimena
Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors.
Massimo Breccia; Daniela Diverio; Roberto Latagliata; Giuseppina Loglisci; Marco Mancini; Adriano Salaroli; Alessandra Serrao; Giuliana Alimena
Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib.
Massimo Breccia; Giuliana Alimena
Are there real benefits of hypomethylating agents for therapy-related myeloid neoplasms?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Massimo Breccia (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Massimo Breccia; Giuliana Alimena
Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors.
Leukemia research 2013;37(6):713-20.
2013: Massimo Breccia; Daniela Diverio; Roberto Latagliata; Giuseppina Loglisci; Marco Mancini; Adriano Salaroli; Alessandra Serrao; Giuliana Alimena
Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib.
Cancer letters 2013;333(1):32-5.
2013: Massimo Breccia; Giuliana Alimena
Are there real benefits of hypomethylating agents for therapy-related myeloid neoplasms?
Leukemia research 2013;37(5):485-6.
2013: Massimo Breccia; Roberto Latagliata; Giuseppina Loglisci; Maria Giovanna Loglisci; Clara Minotti; Adriano Salaroli; Francesco Lo Coco
Influence of time to complete remission and duration of all-trans retinoic acid therapy on the relapse risk in patients with acute promyelocytic leukemia receiving AIDA protocols.
Leukemia research 2013;37(4):383-5.
2013: Anna Paola Iori; Fiammetta Natalino; Salvatore Perrone; Maria Cristina Puzzolo; Emilia Scalzulli; Giovanni Fernando Torelli; Veronica Valle; Walter Barberi; Massimo Breccia; Corrado Girmenia; Robin Foà
The limit for chronic myeloid leukemia relapse after allogeneic hematopoietic stem cell transplant moves ever forward: when can you safely talk about healing?
Leukemia & lymphoma 2013;54(3):669-70.
2013: Massimo Breccia; Giuseppina Loglisci; Adriano Salaroli; Giuliana Alimena
Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine.
Annals of hematology 2013;92(3):411-2.
2013: Massimo Breccia; Maria Teresa Voso; Giuliana Alimena
Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far?
Leukemia research 2013;37(2):204-5.
2013: Alessandra Serrao; Irene Zacheo; Giuliana Alimena; Giuseppina Loglisci; Adriano Salaroli; Massimo Breccia
Azacitidine followed by radiotherapy as effective treatment for chronic myelomonocytic leukemia with extramedullary localization.
Leukemia & lymphoma 2013;54(2):411-2.
2013: Massimo Breccia; Matteo Molica; Adriano Salaroli; Giuliana Alimena
Systematic review of dasatinib in chronic myeloid leukemia.
OncoTargets and therapy 2013;6():257-65.
2013: Roberto Latagliata; Giuseppina Loglisci; Marco Mancini; Mauro Nanni; Michelina Santopietro; Giuseppe Visani; Paola Volpicelli; Federico Vozella; Sara Barulli; Massimo Breccia; Ida Carmosino; Daniela Diverio; Vincenzo Federico; Paola Finsinger; Alessandro Isidori; Giuliana Alimena
Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia.
Acta haematologica 2013;129(2):126-34.
2013: Esther Natalie Oliva; Giuseppe A Palumbo; Antonella Poloni; Alessandra Ricco; Carmela Rigolino; Filippo Rodà; Grazia Sanpaolo; Antonio Volpe; Giuliana Alimena; Maria Antonietta Aloe-Spiriti; Massimo Breccia; Agostino Cortelezzi; Maria Cuzzola; Carlo Finelli; Sara Galimberti; Riccardo Ghio; Carmelo Laganà; Fortunato Morabito; Francesco Nobile; Roberto Latagliata
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.
Annals of hematology 2013;92(1):25-32.
2012: Massimo Breccia; Giuseppina Loglisci; Adriano Salaroli; Alessandra Serrao; Irene Zacheo; Giuliana Alimena
Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia.
British journal of haematology 2012;159(5):612-3.
2012: Massimo Breccia; Giuliana Alimena
Can we safely discontinue imatinib? Searching for new endpoints in CML: a standardized definition of "cure".
Leukemia research 2012;36(12):1498-9.
2012: Massimo Breccia; Giuliana Alimena
Suboptimal response in chronic myeloid leukemia patients treated with imatinib: early identification and new therapeutic challenges.
Cancer letters 2012;325(1):18-25.
2012: Massimo Breccia; Paola Finsinger; Roberto Latagliata; Giuseppina Loglisci; Mauro Nanni; Luigi Petrucci; Adriano Salaroli; Michelina Santopietro; Alessandra Serrao; Paola Volpicelli; Giuliana Alimena
Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experience.
Leukemia & lymphoma 2012;53(12):2439-43.
2012: Safaa M Ramadan; Cristina Papayannidis; William Arcese; Franco Aversa; Andrea Bacigalupo; Massimo Breccia; Agnese Camboni; Luca Cupelli; Ambra Di Veroli; Anna Paola Iori; Francesco Lo Coco
Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era.
Haematologica 2012;97(11):1731-5.
2012: Adriano Salaroli; Alessandra Serrao; Giuliana Alimena; Giuseppina Loglisci; Massimo Breccia
Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes.
Annals of hematology 2012;91(11):1823-4.
2012: Massimo Breccia; Gioia Colafigli; Paola Finsinger; Giuseppina Loglisci; Luigi Petrucci; Adriano Salaroli; Alessandra Serrao; Giuliana Alimena
Evaluation of prognostic factors for overall survival in patients with chronic myelomonocytic leukemia by different scoring systems: which is the best?
Leukemia & lymphoma 2012;53(10):2073-4.
2012: Massimo Breccia; Mario Tiribelli; Giuliana Alimena
Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data.
Critical reviews in oncology/hematology 2012;84(1):93-100.
2012: Massimo Breccia; Giuliana Alimena
How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages.
Cancer letters 2012;322(2):127-32.
2012: Fabio Efficace; F Gherlinzoni; A Iurlo; Giuliana Alimena; M Baccarani; Massimo Breccia; Fausto Castagnetti; F Cottone; S Pardini; A R Rossi; Gianantonio Rosti; M Salvucci; Mario Tiribelli; M Vignetti; F Mandelli
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study.
British journal of cancer 2012;107(6):904-9.
2012: Massimo Breccia; Paola Finsinger; Roberto Latagliata; Giuseppina Loglisci; Marco Mancini; Adriano Salaroli; Alessandra Serrao; Irene Zacheo; Giuliana Alimena
The EUTOS score identifies chronic myeloid leukeamia patients with poor prognosis treated with imatinib first or second line.
Leukemia research 2012;36(9):e209-10.
2012: Massimo Breccia; Gioia Colafigli; Vincenzo Federico; Paola Finsinger; Roberto Latagliata; Giuseppina Loglisci; Luigi Petrucci; Adriano Salaroli; Michelina Santopietro; Alessandra Serrao; Giuliana Alimena
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
Annals of hematology 2012;91(9):1345-9.
2012: Massimo Breccia; Giuseppina Loglisci; Marco Mancini; Luigi Petrucci; Adriano Salaroli; Alessandra Serrao; Giuliana Alimena
5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.
Leukemia & lymphoma 2012;53(8):1558-60.
2012: Massimo Breccia; Fabio Efficace; Giuliana Alimena
Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf?
Leukemia research 2012;36(7):813-4.
2012: Massimo Breccia; Fabio Efficace; Giuliana Alimena
Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Leukemia research 2012;36(7):804-5.
2012: Massimo Breccia; Giuseppina Loglisci; Luigi Petrucci; Adriano Salaroli; Alessandra Serrao; Irene Zacheo; Giuliana Alimena
Combination of azacitidine and ESA in myelodysplastic patients: the need for prospective studies.
Leukemia research 2012;36(6):682-3.
2012: Massimo Breccia; Francesco Lo Coco
Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease.
Expert opinion on pharmacotherapy 2012;13(7):1031-43.
2012: Massimo Breccia; Paola Finsinger; Giuseppina Loglisci; Luigi Petrucci; Adriano Salaroli; Alessandra Serrao; Giuliana Alimena
Neutropenia at baseline could indicate poor prognosis in low/intermediate risk myelodysplastic syndrome patients.
Leukemia research 2012;36(5):546-7.
2012: Massimo Breccia; Laura Cannella; Paola Finsinger; Giuseppina Loglisci; Marco Mancini; Adriano Salaroli; Michelina Santopietro; Alessandra Serrao; Giuliana Alimena
Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response.
Leukemia & lymphoma 2012;53(5):985-6.
2012: Vincenzo Federico; Anna Levi; Giuseppina Loglisci; Giovanna Mansueto; Caterina Mercanti; Pellegrino Musto; Maria Teresa Petrucci; Massimo Breccia; Claudio Cartoni; Giuliana Alimena
Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
Clinical advances in hematology & oncology : H&O 2012;10(4):266-8.
2012: Massimo Breccia; Giuseppina Loglisci; Adriano Salaroli; Alessandra Serrao; Giuliana Alimena
Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index.
Leukemia research 2012;36(4):e66-7.
2012: Corrado Girmenia; Roberto Latagliata; Giuseppina Loglisci; Angela Matturro; Giovanna Meloni; Giuliana Alimena; Massimo Breccia; Saveria Capria; Claudio Cartoni; Robin Foà; Anna Maria Frustaci; Giuseppe Gentile; Clara Minotti; Silvia Maria Trisolini; Alessandra Micozzi
Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.
Haematologica 2012;97(4):560-7.
2012: Laura Cannella; Gioia Colafigli; Maria Rosaria De Cuia; Giuseppina Loglisci; Mauro Nanni; Adriano Salaroli; Alessandra Serrao; Giuliana Alimena; Massimo Breccia
Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia.
Leukemia & lymphoma 2012;53(3):497-8.
2012: Massimo Breccia; Paola Finsinger; Giuseppina Loglisci; Adriano Salaroli; Alessandra Serrao; Giuliana Alimena
MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine.
Haematologica 2012;97(2):e2.
2012: Massimo Breccia; Giuliana Alimena
Isolated myeloid sarcoma without bone marrow involvement.
Clinical advances in hematology & oncology : H&O 2012;10(1):66-7.
2011: Massimo Breccia; Paola Finsinger; Giuseppina Loglisci; Adriano Salaroli; Alessandra Serrao; Giuliana Alimena
The degree of anemia has an impact on survival in myelodysplastic syndrome patients classified with WPSS.
Haematologica 2011;96(12):e45.
2011: Massimo Breccia; Laura Cannella; Gioia Colafigli; Giuseppina Loglisci; Adriano Salaroli; Alessandra Serrao; Giuliana Alimena
Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences.
Leukemia research 2011;35(11):e215-6.
2011: Massimo Breccia; Vincenzo Federico; Giuseppina Loglisci; Adriano Salaroli; Alessandra Serrao; Giuliana Alimena
Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes.
Haematologica 2011;96(10):e41-2.
2011: Massimo Breccia; Fausto Castagnetti; francesco cavazzini; Carmen Fava; Antonella Gozzini; Roberto Latagliata; Luigiana Luciano; Fabrizio Pane; Patrizia Pregno; Giovanna Rege-Cambrin; Gianantonio Rosti; Antonella Russo Rossi; Valeria Santini; Simona Sica; Giorgina Specchia; Fabio Stagno; Paolo Vigneri; Elisabetta Abruzzese; Mario Annunziata; Giuliana Alimena
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.
Haematologica 2011;96(10):1457-61.
2011: Massimo Breccia; Gianna Maria D'Elia; Giuseppina Loglisci; Maurizio Martelli; Francesca Romana Mauro; Mauro Nanni; Adriano Salaroli; Giuliana Alimena
5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
Leukemia research 2011;35(10):1409-11.
2011: Roberto Latagliata; Francesco Lo Coco; Franco Mandelli; Giovanni Martinelli; Lorella Melillo; Maria Concetta Petti; Serena Rupoli; Flavia Salvi; Marco Sborgia; Anna Tonso; Adriano Venditti; Marco Vignetti; Donatella Vincelli; Giuseppe Avvisati; Massimo Breccia; Anna Candoni; Giuseppe Cimino; Francesco Di Raimondo; Paola Fazi; Maria Grazia Kropp
GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors.
British journal of haematology 2011;154(5):564-8.
2011: Massimo Breccia; Giuliana Alimena
The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose.
Expert opinion on pharmacotherapy 2011;12(13):2075-87.
2011: Roberto Latagliata; Luigiana Luciano; Enrico Montefusco; Pellegrino Musto; Ubaldo Occhini; Patrizia Pregno; Antonella Russo Rossi; Giannantonio Rosti; Valeria Santini; Federica Sorà; Fabio Stagno; Mario Tiribelli; Stefano Ulisciani; Paolo Vigneri; Mario Annunziata; Gianni Binotto; Massimo Breccia; Fausto Castagnetti; Francesco Cavazzini; Elena Crisà; Carmen Fava; Costanzo Feo; Antonella Gozzini; Elisabetta Abruzzese; Giuliana Alimena
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.
Leukemia research 2011;35(9):1164-9.
2011: Massimo Breccia; Laura Cicconi; Laura Giannì; Roberto Latagliata; Clara Minotti; Francesco Lo Coco
Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia.
Haematologica 2011;96(9):1390-1.
2011: Massimo Breccia; Giuliana Alimena
Nilotinib and dasatinib first-line: are we ready for imatinib replacement?
Leukemia research 2011;35(9):1153-5.
2011: Massimo Breccia; Giuliana Alimena
The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era.
Critical reviews in oncology/hematology 2011;79(2):135-43.
2011: Giuseppina Loglisci; Marco Mancini; Mauro Nanni; Adriano Salaroli; Michelina Santopietro; Alessandra Serrao; Maria Giovanna Loglisci; Massimo Breccia; Laura Cannella; Rosa De Cuia; Vincenzo Federico; Giuliana Alimena
Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
Leukemia & lymphoma 2011;52(7):1372-5.
2011: Valentina Gianfelici; Daniela Diverio; Massimo Breccia; Sonia Buffolino; Valentina Derme; Attilio Di Lascio; Marilisa Marinelli; Simona Santangelo; Giovanna Meloni; Robin Foà
A novel point mutation within the juxtamembrane domain of the flt3 gene in acute myeloid leukemia.
Annals of hematology 2011;90(7):845-6.
2011: Paola Volpicelli; Roberto Latagliata; Ida Carmosino; Massimo Breccia; Federico Vozella; Marco Mancini; Laura Cannella; Giuliana Alimena
Familial occurrence of myelodysplastic syndrome with del(5q).
Leukemia & lymphoma 2011;52(6):1143-5.
2011: Massimo Breccia; Fabio Stagno; Antonella Gozzini; Elisabetta Abruzzese; Roberto Latagliata; Antonella Russo Rossi; Federica Sorà; Raffaele Porrini; Paolo Vigneri; Malgorzata Trawinska; Enrico Montefusco; Simona Sica; Giorgina Specchia; Valeria Santini; Giuliana Alimena
Hammersmith score application identifies chronic myeloid leukemia patients with poor prognosis before treatment with second-generation tyrosine kinase inhibitors.
American journal of hematology 2011;86(6):523-5.
2011: Massimo Breccia; Giuliana Alimena
Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2011;25(3):147-57.
2011: Massimo Breccia; Laura Cannella; Daniela Diverio; Vincenzo Federico; Giuseppina Loglisci; Mauro Nanni; Luigi Petrucci; Adriano Salaroli; Michelina Santopietro; Alessandra Serrao; Maria Stefania De Propris; Giuliana Alimena
Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib.
Leukemia research 2011;35(6):e91-2.
2011: Massimo Breccia; Laura Cannella; Antonietta Ferretti; Roberto Latagliata; Giuseppina Loglisci; Mauro Nanni; Esther N Oliva; Michelina Santopietro; Rita Barzotti; Giuliana Alimena
Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
Leukemia research 2011;35(6):e69-70.
2011: Massimo Breccia; L Cannella; M Santopietro; G Loglisci; V Federico; A Salaroli; Mauro Nanni; Marco Mancini; Giuliana Alimena
5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3.
Leukemia 2011;25(4):736-7.
2011: Giuliana Alimena; Massimo Breccia; Pellegrino Musto; Daniela Cilloni; Fiorella D'Auria; Roberto Latagliata; Grazia Sanpaolo; Enrico Gottardi; Giuseppe Saglio; Franco Mandelli
Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes.
Leukemia research 2011;35(4):504-7.
2011: Massimo Breccia; Francesco Lo Coco
Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy.
Expert opinion on biological therapy 2011;11(2):225-34.
2011: Massimo Breccia; Vincenzo Federico; Roberto Latagliata; Caterina Mercanti; Gianna Maria D'Elia; Laura Cannella; Giuseppina Loglisci; Adriano Salaroli; Michelina Santopietro; Giuliana Alimena
Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.
Leukemia research 2011;35(2):159-62.
2011: Massimo Breccia; Fabio Efficace; Giuliana Alimena
Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?
Cancer letters 2011;300(2):115-21.
2011: Massimo Breccia; Vincenzo Federico; Corrado Girmenia; Roberto Latagliata; Giuseppina Loglisci; Luigi Petrucci; Adriano Salaroli; Michelina Santopietro; Alessandra Serrao; Giuliana Alimena
Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase.
Mediterranean journal of hematology and infectious diseases 2011;3(1):e2011021.
2011: Corrado Girmenia; Roberto Latagliata; Caterina Mercanti; Alessandra Micozzi; Salvatore Giacomo Morano; Massimiliano Rea; Michela Sali; Veronica Valle; Giuliana Alimena; Massimo Breccia; Gregorio Antonio Brunetti; Annalisa De Vellis; Giovanni Delogu; Vincenzo Federico; Robin Foà; Giuseppe Gentile
Management of the 2009 A/H1N1 influenza pandemic in patients with hematologic diseases: a prospective experience at an Italian center.
Acta haematologica 2011;126(1):1-7.
2010: Massimo Breccia; Giuliana Alimena
NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.
Expert opinion on therapeutic targets 2010;14(11):1157-76.
2010: Roberto Latagliata; Massimo Breccia; Ida Carmosino; Laura Cannella; Rosa De Cuia; Daniela Diverio; Annamaria Frustaci; Giuseppina Loglisci; Marco Mancini; Michelina Santopietro; Caterina Stefanizzi; Paola Volpicelli; Federico Vozella; Giuliana Alimena
"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia.
Leukemia research 2010;34(11):1472-5.
2010: Gianna Maria D'Elia; Federico De Angelis; Massimo Breccia; Giorgia Annechini; Sara Panfilio; Roberta Danieli; Elena Cavalieri; Alessandro Pulsoni
Efficacy of bendamustine as salvage treatment in an heavily pre-treated Hodgkin lymphoma.
Leukemia research 2010;34(11):e300-1.
2010: Francesco Lo Coco; Giuseppe Avvisati; Marco Vignetti; Massimo Breccia; Eugenio Gallo; Alessandro Rambaldi; Francesca Paoloni; Giuseppe Fioritoni; Felicetto Ferrara; Giorgina Specchia; Giuseppe Cimino; Daniela Diverio; Erika Borlenghi; Giovanni Martinelli; Francesco Di Raimondo; Eros Di Bona; Paola Fazi; Antonio Peta; Alberto Bosi; Angelo Michele Carella; Francesco Fabbiano; Enrico M Pogliani; Maria Concetta Petti; Sergio Amadori; Franco Mandelli
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.
Blood 2010;116(17):3171-9.
2010: Massimo Breccia
Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
Nature reviews. Clinical oncology 2010;7(10):557-8.
2010: Massimo Breccia; Giuliana Alimena
Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
Expert opinion on drug safety 2010;9(5):713-21.
2010: Massimo Breccia; Michelina Santopietro; Giuseppina Loglisci; Fabio Stagno; Laura Cannella; Ida Carmosino; Giuliana Alimena
Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy.
Leukemia research 2010;34(8):e224-5.
2010: Massimo Breccia
From FAB to 2008 WHO classification: the wide heterogeneity of refractory anemia subtype among different countries.
Leukemia research 2010;34(8):967-8.
2010: Massimo Breccia; Monica Bocchia; Laura Cannella; Marzia Defina; Micaela Ippoliti; Giuseppina Loglisci; Michelina Santopietro; Francesco Lauria; Giuliana Alimena
Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance.
British journal of haematology 2010;150(2):240-2.
2010: Massimo Breccia; Laura Cannella; Caterina Stefanizzi; Roberto Latagliata; Mauro Nanni; Daniela Diverio; Michelina Santopietro; Vincenzo Federico; Giuliana Alimena
Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.
Hematological oncology 2010;28(2):89-92.
2010: Massimo Breccia; Roberto Latagliata; Laura Cannella; Ida Carmosino; Michelina Santopietro; Giuseppina Loglisci; Vincenzo Federico; Giuliana Alimena
Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients.
Leukemia & lymphoma 2010;51(5):783-8.
2010: Massimo Breccia; Maurizio Muscaritoli; Laura Cannella; Giuseppina Loglisci; Michelina Santopietro; Giuliana Alimena
Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment.
Leukemia research 2010;34(5):e122-4.
2010: Massimo Breccia; Giuliana Alimena
Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia.
Leukemia research 2010;34(2):129-34.
2010: Massimo Breccia; Francesca Palandri; Anna Paola Iori; Elisabetta Colaci; Roberto Latagliata; Fausto Castagnetti; Giovanni Fernando Torelli; Sara Usai; Veronica Valle; Giovanni Martinelli; Gianantonio Rosti; Robin Foà; Michele Baccarani; Giuliana Alimena
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
Leukemia research 2010;34(2):143-7.
2010: Massimo Breccia; Saveria Capria; Anna Paola Iori; Robin Foà; Giuliana Alimena; Giovanna Meloni
Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib.
Acta haematologica 2010;124(3):150-2.
2010: Massimo Breccia; Giuseppina Loglisci; Adriano Salaroli; Laura Cannella; Michelina Santopietro; Giuliana Alimena
Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response.
Acta haematologica 2010;124(1):46-8.
2010: A Fama; A Rago; F Gioiosa; C Marzano; Roberto Latagliata; C Mammì; C Laganà; Gianna Maria D'Elia; Luisa Bizzoni; Stefania Trasarti; Antonio Ferretti; Massimo Breccia; Oliviero Riggio; Agostino Tafuri
[Budd-Chiari syndrome and splanchnic vein thrombosis: masked myeloproliferative neoplasms and JAK2V617F].
La Clinica terapeutica 2010;161(2):169-71.
2009: Gianantonio Rosti; Francesca Palandri; Fausto Castagnetti; Massimo Breccia; Luciano Levato; Gabriele Gugliotta; Adele Capucci; Michele Cedrone; Carmen Fava; Tamara Intermesoli; Giovanna Rege Cambrin; Fabio Stagno; Mario Tiribelli; Marilina Amabile; Simona Luatti; Angela Poerio; Simona Soverini; Nicoletta Testoni; Giovanni Martinelli; Giuliana Alimena; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.
Blood 2009;114(24):4933-8.
2009: Roberto Latagliata; Angela Rago; Antonio Spadea; Cristina Santoro; Ida Carmosino; Massimo Breccia; Laura Napoleone; Angelo Fama; Francesca Biondo; Paola Volpicelli; Federico Vozella; Caterina Stefanizzi; Maria Concetta Petti; Giuliana Alimena; Maria Gabriella Mazzucconi
Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results.
International journal of hematology 2009;90(4):486-91.
2009: Massimo Breccia; Anna Maria Frustaci; Laura Cannella; Caterina Stefanizzi; Roberto Latagliata; Claudio Cartoni; Daniela Diverio; Anna Guarini; Mauro Nanni; Angela Rago; Giuseppe Cimino; Giuliana Alimena
Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients.
Hematological oncology 2009;27(3):148-53.
2009: Giuliana Alimena; Massimo Breccia; Roberto Latagliata; Sara Grammatico; Angela Matturro; Saveria Capria; Maria Stefania De Propris; Daniela Diverio; Giovanna Meloni
Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizations.
Leukemia research 2009;33(8):e134-6.
2009: Massimo Breccia; Giuliana Alimena
The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.
Leukemia research 2009;33(7):871-5.
2009: Massimo Breccia; Laura Cannella; Caterina Stefanizzi; Roberto Latagliata; Angelo Fama; Michelina Santopietro; Giuliana Alimena
WPSS versus simplified myelodysplastic syndrome risk score: Which is the best tool for prediction of survival in myelodysplastic patients?
Leukemia research 2009;33(7):e93-4.
2009: Massimo Breccia; Giuliana Alimena
Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.
Current drug targets 2009;10(6):530-6.
2009: Caterina Stefanizzi; Massimo Breccia; Michelina Santopietro; Serelina Coluzzi; Laura Cannella; Gabriella Girelli; Giuliana Alimena
Unusual association of paroxysmal cold hemoglobinuria as the first sign of disease in myelodysplastic patient.
International journal of hematology 2009;89(5):720-1.
2009: Massimo Breccia; Anna Maria Frustaci; Laura Cannella; Simona Soverini; Caterina Stefanizzi; Vincenzo Federico; Sara Grammatico; Michelina Santopietro; Giuliana Alimena
Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?
Cancer chemotherapy and pharmacology 2009;64(1):195-7.
2009: Massimo Breccia; Gianna Maria D'Elia; Laura Cannella; Caterina Stefanizzi; Angelo Fama; Vincenzo Federico; Michelina Santopietro; Giuliana Alimena
Platelet count is an independent prognostic factor in myelodysplastic syndromes considered as low risk by French-American-British and World Health Organisation classifications.
Leukemia & lymphoma 2009;50(5):841-3.
2009: Laura Cannella; Massimo Breccia; Caterina Stefanizzi; Laura Napoleone; Michela Santopietro; Giuliana Alimena
Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance.
Leukemia & lymphoma 2009;50(5):848-50.
2009: Massimo Breccia; Laura Cannella; Caterina Stefanizzi; Michelina Santopietro; Rosa De Cuia; Daniela Diverio; Giuliana Alimena
Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
Leukemia research 2009;33(5):645-8.
2009: Massimo Breccia; Daniela Cilloni; Laura Cannella; Caterina Stefanizzi; Agostino Tafuri; Angelo Fama; Michelina Santopietro; Giuseppe Saglio; Giuliana Alimena
Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose.
Cancer chemotherapy and pharmacology 2009;63(6):1161-3.
2009: Fausto Castagnetti; Francesca Palandri; Marilina Amabile; Nicoletta Testoni; Simona Luatti; Simona Soverini; Ilaria Iacobucci; Massimo Breccia; Giovanna Rege-Cambrin; Fabio Stagno; Giorgina Specchia; Piero Galieni; Franco Iuliano; Fabrizio Pane; Giuseppe Saglio; Giuliana Alimena; giovanni martinelli; Michele Baccarani; Gianantonio Rosti
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.
Blood 2009;113(15):3428-34.
2009: Claudio Cartoni; Pasquale Niscola; Massimo Breccia; Gregorio Brunetti; Gianna Maria D'Elia; Marco Giovannini; Claudio Romani; Laura Scaramucci; Andrea Tendas; Luca Cupelli; Paolo De Fabritiis; Robin Foa; Franco Mandelli
Hemorrhagic complications in patients with advanced hematological malignancies followed at home: an Italian experience.
Leukemia & lymphoma 2009;50(3):387-91.
2009: Massimo Breccia; Roberto Latagliata; L Cannella; Ida Carmosino; R De Cuia; Annamaria Frustaci; Caterina Stefanizzi; M Santopietro; Giuliana Alimena
Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal.
Leukemia research 2009;33(3):391-4.
2009: Francesca Palandri; Ilaria Iacobucci; Simona Soverini; Fausto Castagnetti; Angela Poerio; Nicoletta Testoni; Giuliana Alimena; Massimo Breccia; Giovanna Rege-Cambrin; Mario Tiribelli; Riccardo Varaldo; Elisabetta Abruzzese; Bruno Martino; Luigiana Luciano; Fabrizio Pane; Giuseppe Saglio; giovanni martinelli; Michele Baccarani; Gianantonio Rosti
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(3):1059-63.
2009: Francesca Palandri; Fausto Castagnetti; Giuliana Alimena; Nicoletta Testoni; Massimo Breccia; Simona Luatti; Giovanna Rege-Cambrin; Fabio Stagno; Giorgina Specchia; Bruno Martino; Luciano Levato; Serena Merante; Anna Maria Liberati; Fabrizio Pane; Giuseppe Saglio; Daniele Alberti; giovanni martinelli; Michele Baccarani; Gianantonio Rosti
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.
Haematologica 2009;94(2):205-12.
2009: Francesca Palandri; Nicoletta Testoni; Simona Luatti; Giulia Marzocchi; Carmen Baldazzi; Monica Stacchini; Fausto Castagnetti; Massimo Breccia; Giorgina Specchia; Fabrizio Pane; Giuseppe Saglio; giovanni martinelli; Michele Baccarani; Gianantonio Rosti
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results.
Leukemia & lymphoma 2009;50(1):114-8.
2009: Annamaria Frustaci; Massimo Breccia; L Cannella; Caterina Stefanizzi; Giuliana Alimena
Occurrence of colon adenocarcinoma in chronic myeloid leukemia patients treated with imatinib: report of two cases and review of the literature.
Leukemia research 2009;33(1):200-1.
2008: Massimo Breccia; Caterina Stefanizzi; Laura Cannella; Roberto Latagliata; Anna Maria Frustaci; Ida Carmosino; Michelina Santopietro; Giuliana Alimena
Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia.
Leukemia & lymphoma 2008;49(12):2328-32.
2008: Roberto Latagliata; Massimo Breccia; Paola Fazi; Simona Iacobelli; giovanni martinelli; Francesco Di Raimondo; Marco Sborgia; Francesco Fabbiano; Maria Teresa Pirrotta; Alfonso Zaccaria; Sergio Amadori; Cecilia Caramatti; Franca Falzetti; Anna Candoni; Daniele Mattei; Monica Morselli; Giuliana Alimena; Marco Vignetti; Michele Baccarani; Franco Mandelli
Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia.
British journal of haematology 2008;143(5):681-9.
2008: Massimo Breccia; Roberto Latagliata; Ida Carmosino; Laura Cannella; Daniela Diverio; Anna Guarini; Maria Stefania De Propris; Maria Concetta Petti; Giuseppe Avvisati; Giuseppe Cimino; Franco Mandelli; Francesco Lo Coco
Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin.
Haematologica 2008;93(12):1918-20.
2008: Francesca Palandri; Fausto Castagnetti; Nicoletta Testoni; Simona Luatti; Giulia Marzocchi; Simona Bassi; Massimo Breccia; Giuliana Alimena; Ester Pungolino; Giovanna Rege-Cambrin; Riccardo Varaldo; Maurizio Miglino; Giorgina Specchia; Elisa Zuffa; Felicetto Ferrara; Monica Bocchia; Giuseppe Saglio; Fabrizio Pane; Daniele Alberti; giovanni martinelli; Michele Baccarani; Gianantonio Rosti
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Haematologica 2008;93(12):1792-6.
2008: P Volpicelli; Roberto Latagliata; Massimo Breccia; Ida Carmosino; Caterina Stefanizzi; L Napoleone; F Vozella; A Levi; F Natalino; Giuliana Alimena
Pregnancy in patients with myelodysplastic syndromes (MDS).
Leukemia research 2008;32(10):1605-7.
2008: Massimo Breccia; Maurizio Muscaritoli; L Cannella; Caterina Stefanizzi; Annamaria Frustaci; Giuliana Alimena
Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib.
Leukemia research 2008;32(10):1626-8.
2008: Massimo Breccia; L Cannella; Annamaria Frustaci; Caterina Stefanizzi; Gianna Maria D'Elia; Giuliana Alimena
Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: further evidence for the arbitrary nature of current classification systems.
Leukemia & lymphoma 2008;49(7):1292-6.
2008: Massimo Breccia; Fabiana Gentilini; Laura Cannella; Roberto Latagliata; Ida Carmosino; Annamaria Frustaci; Giuliana Alimena
Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
Leukemia research 2008;32(7):1022-5.
2008: Massimo Breccia; Roberto Latagliata; Ida Carmosino; Anna Guarini; Daniela Diverio; Rosaria De Cuia; Giuseppe Cimino; Giuliana Alimena
Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients.
Leukemia & lymphoma 2008;49(5):994-7.
2008: Francesca Palandri; Ilaria Iacobucci; Fausto Castagnetti; Nicoletta Testoni; Angela Poerio; Marilina Amabile; Massimo Breccia; Tamara Intermesoli; Francesco Iuliano; Giovanna Rege-Cambrin; Mario Tiribelli; Maurizio Miglino; Fabrizio Pane; Giuseppe Saglio; giovanni martinelli; Gianantonio Rosti; Michele Baccarani
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.
Haematologica 2008;93(5):770-4.
2008: Massimo Breccia; Laura Cannella; Annamaria Frustaci; Caterina Stefanizzi; Anna Levi; Giuliana Alimena
Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience.
Leukemia research 2008;32(5):835-6.
2008: Massimo Breccia; Laura Cannella; Enrico Montefusco; Annamaria Frustaci; Matteo Pacilli; Giuliana Alimena
Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases.
Leukemia research 2008;32(3):519-20.
2008: Laura Cannella; Massimo Breccia; Roberto Latagliata; Annamaria Frustaci; Giuliana Alimena
Clinical and prognostic features of patients with myelodysplastic/myeloproliferative syndrome categorized as unclassified (MDS/MPD-U) by WHO classification.
Leukemia research 2008;32(3):514-6.
2008: Massimo Breccia; Maurizio Martelli; Laura Cannella; Eleonora Russo; Erica Finolezzi; Caterina Stefanizzi; Anna Levi; Annamaria Frustaci; Giuliana Alimena
Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma.
Leukemia research 2008;32(2):353-5.
2008: Giuliana Alimena; Massimo Breccia; Luigiana Luciano; Fabrizio Quarantelli; Daniela Diverio; Barbara Izzo; BIAGIO DE ANGELIS; Marco Mancini; Roberto Latagliata; Ida Carmosino; Mauro Nanni; Marco Picardi; Bruno Rotoli; Franco Mandelli; Fabrizio Pane
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
Leukemia research 2008;32(2):255-61.
2008: Massimo Breccia; Giuliana Alimena
Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib.
OncoTargets and therapy 2008;1():49-58.
2008: Roberto Latagliata; Esther Oliva; P Volpicelli; Ida Carmosino; Massimo Breccia; I Vincelli; C Alati; L Napoleone; F Vozella; Francesco Nobile; Giuliana Alimena
Twice-weekly high-dose rHuEpo for the treatment of anemia in patients with low-risk myelodysplastic syndromes.
Acta haematologica 2008;120(2):104-7.
2008: Francesca Palandri; Ilaria Iacobucci; giovanni martinelli; Marilina Amabile; Angela Poerio; Nicoletta Testoni; Simona Soverini; Fausto Castagnetti; Antonio de Vivo; Massimo Breccia; Giorgina Specchia; Elisabetta Abruzzese; Bruno Martino; Daniela Cilloni; Giuseppe Saglio; Fabrizio Pane; Anna Marina Liberati; Gianantonio Rosti; Michele Baccarani
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(1):106-11.
2008: Massimo Breccia; Laura Cannella; Daniela Diverio; Paola Streponi; Mauro Nanni; Caterina Stefanizzi; Fiammetta Natalino; Sergio Mecarocci; Giuliana Alimena
Isolated thrombocytosis as first sign of chronic myeloid leukemia with e6a2 BCR/ABL fusion transcript, JAK2 negativity and complete response to imatinib.
Leukemia research 2008;32(1):177-80.
2007: Massimo Breccia; Maurizio Muscaritoli; Fabiana Gentilini; Roberto Latagliata; Ida Carmosino; F Rossi Fanelli; Giuliana Alimena
Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib.
Leukemia research 2007;31(12):1770-2.
2007: Massimo Breccia; Giuseppe Cimino; Daniela Diverio; Fabiana Gentilini; Franco Mandelli; Francesco Lo Coco
Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia.
Haematologica 2007;92(9):1273-4.
2007: Claudio Cartoni; Gregorio Antonio Brunetti; Gianna Maria D'Elia; Massimo Breccia; Pasquale Niscola; Maria Giulia Marini; Antonio Nastri; Giuliana Alimena; Franco Mandelli; Robin Foà
Cost analysis of a domiciliary program of supportive and palliative care for patients with hematologic malignancies.
Haematologica 2007;92(5):666-73.
2007: Massimo Breccia; Fabiana Gentilini; Anna Guarini; Maria Stefania De Propris; Giuseppe Cimino; Francesco Lo Coco
Haemolytic uremic syndrome during induction therapy in an acute promyelocytic leukemia patient with aberrant phenotype: a possible manifestation of retinoic acid syndrome.
Leukemia & lymphoma 2007;48(4):833-4.
2007: Corrado Girmenia; Eleonora Russo; Ida Carmosino; Massimo Breccia; Francesco Dragoni; Roberto Latagliata; Sergio Mecarocci; Susanna Morano; Caterina Stefanizzi; Giuliana Alimena
Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia.
Annals of hematology 2007;86(4):263-70.
2007: Vincenza Martini; Clara Minotti; Massimo Breccia; Gioia De Angelis; Sonia Buffolino; Montano Mariella; Francesco Lo Coco; Giuseppe Avvisati; Giuseppe Cimino
Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid.
Annals of hematology 2007;86(4):295-7.
2007: Massimo Breccia; Fabiana Gentilini; Giuliana Alimena
Cocaine abuse may influence the response to imatinib in CML patients.
Haematologica 2007;92(3):e41-2.
2007: Massimo Breccia; Laura Cannella; Mauro Nanni; Caterina Stefanizzi; Giuliana Alimena
Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy.
Acta haematologica 2007;118(3):162-4.
2007: Massimo Breccia; Roberto Latagliata; Ida Carmosino; Fabiana Gentilini; Gianna Maria D'Elia; Anna Levi; Fiammetta Natalino; Annamaria Frustaci; Maria Rosaria De Cuia; Giuliana Alimena
Refractory anaemia with excess of blasts in transformation re-evaluated with the WHO criteria: identification of subgroups with different survival.
Acta haematologica 2007;117(4):221-5.
2007: Roberto Latagliata; Ida Carmosino; Massimo Breccia; Antonio Minni; Anna Maria Testi; Nicol Iorio; Francesco Lo Coco; Giuseppe Avvisati; Maria Concetta Petti; Franco Mandelli; Giuseppe Cimino
Late relapses in acute promyelocytic leukaemia.
Acta haematologica 2007;117(2):106-8.
2007: Massimo Breccia; Giuseppe Avvisati; Roberto Latagliata; Ida Carmosino; Anna Guarini; Maria Stefania De Propris; Fabiana Gentilini; Maria Concetta Petti; Giuseppe Cimino; Franco Mandelli; Francesco Lo Coco
Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features.
Leukemia 2007;21(1):79-83.
2006: Massimo Breccia; Daniela Diverio; Fabrizio Pane; Mauro Nanni; Eleonora Russo; Francesca Biondo; Annamaria Frustaci; Fabiana Gentilini; Giuliana Alimena
Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon.
Leukemia research 2006;30(12):1577-9.
2006: Massimo Breccia; Francesca Biondo; Roberto Latagliata; Ida Carmosino; Franco Mandelli; Giuliana Alimena
Identification of risk factors in atypical chronic myeloid leukemia.
Haematologica 2006;91(11):1566-8.
2006: Giuliana Alimena; Massimo Breccia; Roberto Latagliata; Ida Carmosino; Eleonora Russo; Francesca Biondo; Daniela Diverio; Marco Mancini; Mauro Nanni; Franco Mandelli
Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
Cancer 2006;107(5):1008-13.
2006: Ilaria Iacobucci; Giuseppe Saglio; Gianantonio Rosti; Nicoletta Testoni; Fabrizio Pane; Marilina Amabile; Angela Poerio; Simona Soverini; Simona Bassi; Daniela Cilloni; Renato Bassan; Massimo Breccia; Francesco Lauria; Barbara Izzo; Serena Merante; Francesco Frassoni; Stefania Paolini; Enrico Montefusco; Michele Baccarani; giovanni martinelli
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(10):3037-42.
2006: Maria José Carnicer; Sergio Bernardini; Lorenza Bellincampi; Nélida I Noguera; Marzia Nuccetelli; Emanuele Ammatuna; Massimo Breccia; Francesco Lo Coco; Giorgio Federici
Role of gamma-glutamyl cysteine synthetase (gamma-GCS) gene expression as marker of drug sensitivity in acute myeloid leukemias.
Clinica chimica acta; international journal of clinical chemistry 2006;365(1-2):342-5.
2006: Roberto Latagliata; Velia Bongarzoni; Ida Carmosino; Andrea Mengarelli; Massimo Breccia; Paola Anticoli Borza; Mariella D'Andrea; Gianna Maria D'Elia; Sergio Mecarocci; Susanna Morano; Maria Concetta Petti; Franco Mandelli; Giuliana Alimena
Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(2):281-5.
2006: Massimo Breccia; Ida Carmosino; Francesca Biondo; Marco Mancini; Eleonora Russo; Roberto Latagliata; Giuliana Alimena
Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes.
Leukemia research 2006;30(2):178-82.
2006: Massimo Breccia; Eleonora Russo; Maria Stefania De Propris; Annamaria Frustaci; Giuliana Alimena
Atypical chronic myeloid leukaemia with CD117-positive blast cells treated with imatinib: A report of two cases.
Acta haematologica 2006;116(3):211-2.
2005: Massimo Breccia; Maurizio Muscaritoli; Giuliana Alimena
Reduction of glycosylated hemoglobin with stable insulin levels in a diabetic patient with chronic myeloid leukemia responsive to imatinib.
Haematologica 2005;90 Suppl():ECR21.
2005: Massimo Breccia; Susanna Morano; Mariella D'Andrea; Eleonora Russo; Gianna Maria D'Elia; Giuliana Alimena
Budd-Chiari syndrome as the first manifestation of polycythemia vera in young women with inherited thrombophilic state: an aggressive form of myeloproliferative disorder requiring multidisciplinary management.
European journal of haematology 2005;75(5):396-400.
2005: Massimo Breccia; Mariella D'Andrea; Giuliana Alimena
Can nifedipine and estrogen interaction with imatinib be responsible for gallbladder stone development?
European journal of haematology 2005;75(1):89-90.
2005: Massimo Breccia; Andrea Mengarelli; Marco Mancini; Francesca Biondo; Fabiana Gentilini; Roberto Latagliata; Franco Mandelli; Giuliana Alimena
Myelodysplastic syndromes in patients under 50 years old: a single institution experience.
Leukemia research 2005;29(7):749-54.
2005: Roberto Latagliata; Latagliata Roberto; Massimo Breccia; Breccia Massimo; Ida Carmosino; Carmosino Ida; Chiara Sarlo; Sarlo Chiara; Enrico Montefusco; Montefusco Enrico; Marco Mancini; Mancini Marco; Fiammetta Natalino; Natalino Fiammetta; Antonio Chistolini; Chistolini Antonio; Rosa De Cuia; De Cuia Rosa; Eleonora Russo; Russo Eleonora; Giacomo Salvatore Morano; Morano Salvatore Giacomo; Francesca Biondo; Biondo Francesca; Antonio Spadea; Spadea Antonio; Franco Mandelli; Mandelli Franco; Giuliana Alimena; Alimena Giuliana
Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment.
Leukemia research 2005;29(3):287-91.
2005: Massimo Breccia; Ida Carmosino; Eleonora Russo; Susanna Morano; Roberto Latagliata; Giuliana Alimena
Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib.
European journal of haematology 2005;74(2):121-3.
2005: Giuliana Alimena; Massimo Breccia; Marco Mancini; Daniela Diverio; Mauro Nanni; Maria Stefania De Propris; Giuseppe Cimino; Fabrizio Pane; Franco Mandelli
Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status.
Leukemia 2005;19(2):287-9.
2005: Massimo Breccia; Gianna Maria D'Elia; Mariella D'Andrea; Roberto Latagliata; Giuliana Alimena
Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib.
European journal of haematology 2005;74(1):89-90.
2005: Massimo Breccia; Marco Mancini; Mauro Nanni; Gianna Maria D'Elia; Ida Carmosino; Roberto Latagliata; Chiara Sarlo; Franco Mandelli; Giuliana Alimena
Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation.
Leukemia research 2005;29(1):33-9.
2004: Massimo Breccia; Maurizio Muscaritoli; Zaira Aversa; F Mandelli; Giuliana Alimena
Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(22):4653-5.
2004: Massimo Breccia; Franco Mandelli; Maria Concetta Petti; Mariella D'Andrea; Edoardo Pescarmona; Stefano A Pileri; Ida Carmosino; Eleonora Russo; Paolo De Fabritiis; Giuliana Alimena
Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution.
Leukemia research 2004;28(11):1165-9.
2004: Massimo Breccia; Gianna Maria D'Elia; Gabriella Girelli; Stefania Vaglio; Fabiana Gentilini; Sarlo Chiara; Giuliana Alimena
Paroxysmal cold haemoglobinuria as a tardive complication of idiopathic myelofibrosis.
European journal of haematology 2004;73(4):304-6.
2004: Francesco Lo Coco; Giuseppe Cimino; Massimo Breccia; Nélida I Noguera; Daniela Diverio; Erica Finolezzi; Enrico Pogliani; Eros Di Bona; Concetta Micalizzi; Mariagrazia Kropp; Adriano Venditti; Agostino Tafuri; Franco Mandelli
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia.
Blood 2004;104(7):1995-9.
2004: Massimo Breccia; Maria Rosaria De Cuia; Gianna Maria D'Elia; Biondo Francesca; Franco Mandelli; Giuliana Alimena
Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia.
Haematologica 2004;89(7):ECR20.
2004: Massimo Breccia; Roberto Latagliata; Andrea Mengarelli; Francesca Biondo; Franco Mandelli; Giuliana Alimena
Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution.
Haematologica 2004;89(7):866-8.
2004: Ida Carmosino; Roberto Latagliata; Giuseppe Avvisati; Massimo Breccia; Erica Finolezzi; Francesco Lo Coco; Maria Concetta Petti
Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
Haematologica 2004;89(5):615-7.
2004: Massimo Breccia; Mariella D'Andrea; Corrado Girmenia; Ugo Bottoni; Ida Carmosino; Francesca Biondo; Giuliana Alimena
Recurrent Sweet's syndrome in acute myeloid leukemia successfully treated with amphotericin B.
Haematologica 2004;89(4):ELT04.
2004: Massimo Breccia; Mauro Nanni; Francesca Mancini; Eleonora Russo; Sergio Mecarocci; Giuliana Alimena
Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib.
Haematologica 2004;89(4):ECR11.
2004: G Alimena; Massimo Breccia; M Mancini; G Ferranti; Lidia De Felice; C Gallucci; Franco Mandelli
Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome.
Leukemia 2004;18(2):361-2.
2004: Massimo Breccia; Giuseppe Gentile; Pietro Martino; Maria Concetta Petti; Eleonora Russo; Marco Mancini; Giuliana Alimena
Acute myeloid leukemia secondary to a myelodysplastic syndrome with t(3;3) (q21;q26) in an HIV patient treated with chemotherapy and highly active antiretroviral therapy.
Acta haematologica 2004;111(3):160-2.
2004: Massimo Breccia; Daniela Diverio; Nélida I Noguera; Giuseppe Visani; Alessandra Santoro; Franco Locatelli; Daniela Damiani; Filippo Marmont; Marco Vignetti; Maria Concetta Petti; Francesco Lo Coco
Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy.
Haematologica 2004;89(1):29-33.
2004: Massimo Breccia; Roberto Latagliata; Ida Carmosino; F Mandelli; Giuliana Alimena
Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia.
Leukemia 2004;18(1):182.
2003: Francesco Lo Coco; Massimo Breccia; Nélida I Noguera; Wilson H Miller
Diagnostic value of detecting fusion proteins derived from chromosome translocations in acute leukaemia.
Best practice & research. Clinical haematology 2003;16(4):653-70.
2003: Francesco Lo Coco; Massimo Breccia; Daniela Diverio
The importance of molecular monitoring in acute promyelocytic leukaemia.
Best practice & research. Clinical haematology 2003;16(3):503-20.
2003: Anna Guarini; Gianluca Gaidano; Francesca Romana Mauro; Daniela Capello; Francesca Mancini; Maria Stefania De Propris; Marco Mancini; Enrica Orsini; Massimo Gentile; Massimo Breccia; Antonio Cuneo; Gianluigi Castoldi; Robin Foa
Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features.
Blood 2003;102(3):1035-41.
2003: Corrado Girmenia; Francesco Lo Coco; Massimo Breccia; Roberto Latagliata; Antonio Spadea; Mariella D'Andrea; Giuseppe Gentile; Alessandra Micozzi; Giuliana Alimena; Pietro Martino; Franco Mandelli
Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen.
Leukemia 2003;17(5):925-30.
2003: Massimo Breccia; Mariella D'Andrea; Andrea Mengarelli; Susanna Morano; Gianna Maria D'Elia; Giuliana Alimena
Granulocytic sarcoma of the pancreas successfully treated with intensive chemotherapy and stem cell transplantation.
European journal of haematology 2003;70(3):190-2.
2003: Massimo Breccia; Ida Carmosino; Daniela Diverio; Silvia De Santis; Maria Stefania De Propris; Atelda Romano; Maria Concetta Petti; Franco Mandelli; Francesco Lo Coco
Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count.
British journal of haematology 2003;120(2):266-70.
2002: Roberto Latagliata; Giuliana Alimena; Ida Carmosino; Massimo Breccia; Paola Anticoli Borza; Velia Bongarzoni; Carolina Copia; Antonio Spadea; Beatrice Pinazzi; Natalia Frattarelli; Felicetto Ferrara; Maria Concetta Petti; Franco Mandelli
Conservative treatment for patients over 80 years with acute myelogenous leukemia.
American journal of hematology 2002;71(4):256-9.
2002: Nélida I Noguera; Massimo Breccia; Mariadomenica Divona; Daniela Diverio; V Costa; Silvia De Santis; Giuseppe Avvisati; M B Pinazzi; Maria Concetta Petti; Franco Mandelli; Francesco Lo Coco
Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol.
Leukemia 2002;16(11):2185-9.
2002: Massimo Breccia; Maria Concetta Petti; Emanuela Ottaviani; Marco Mancini; Gianna Maria D'Elia; Sergio Mecarocci; Giuliana Alimena
Diabetes insipidus as first manifestation of acute myeloid leukaemia with EVI-1-positive, 3q21q26 syndrome and T cell-line antigen expression: what is the EVI-1 gene role?
British journal of haematology 2002;118(2):438-41.
2002: Massimo Breccia; Maria Concetta Petti; Anna Maria Testi; Giorgina Specchia; Felicetto Ferrara; Daniela Diverio; Atelda Romano; V Guerrisi; A Greco; Maria Luisa Fiorella; Marco de Vincentiis; Franco Mandelli; Francesco Lo Coco
Ear involvement in acute promyelocytic leukemia at relapse: a disease-associated 'sanctuary'?
Leukemia 2002;16(6):1127-30.
2002: Maria Concetta Petti; Roberto Latagliata; T Spadea; Antonio Spadea; Enrico Montefusco; Maria Antonietta Aloe-Spiriti; Giuseppe Avvisati; Massimo Breccia; Edoardo Pescarmona; Franco Mandelli
Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.
British journal of haematology 2002;116(3):576-81.
2002: Giovanni F Torelli; Anna Guarini; Gabriella Palmieri; Massimo Breccia; Antonella Vitale; Angela Santoni; Robin Foa
Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission.
British journal of haematology 2002;116(2):299-307.
2002: Massimo Breccia; Giuseppe Cimino; Giuliana Alimena; Sara De Carolis; Francesco Lo Coco; Franco Mandelli
AIDA treatment for high-risk acute promyelocytic leukemia in a pregnant woman at 21 weeks of gestation.
Haematologica 2002;87(2):ELT12.
2002: Roberto Latagliata; Maria Concetta Petti; SUSANNA FENU; Marco Mancini; Maria Antonietta Aloe Spiriti; Massimo Breccia; Gregorio A Brunetti; Giuseppe Avvisati; Francesco Lo Coco; Franco Mandelli
Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem.
Blood 2002;99(3):822-4.
2002: Massimo Breccia; Maria Concetta Petti; Gianna Maria D'Elia; Mariella D'Andrea; Ida Carmosino; Giuliana Alimena
Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen.
European journal of haematology 2002;68(1):1-3.
2001: Maria Concetta Petti; Roberto Latagliata; Massimo Breccia; Giuliana Alimena; Antonio Spadea; Mariella D'Andrea; Marco Mancini; Maria Antonietta Aloe-Spiriti; Franco Mandelli
Spontaneous remission in adult patients with de novo myelodysplastic syndrome: a possible event.
Haematologica 2001;86(12):1277-80.
2001: Massimo Breccia; Corrado Girmenia; Sergio Mecarocci; Claudio Cartoni; Ida Carmosino; Agostino Tafuri; Giuliana Alimena
Ogilvie's syndrome in acute myeloid leukemia: pharmacological approach with neostigmine.
Annals of hematology 2001;80(10):614-6.
2001: Anna Guarini; Massimo Breccia; Enrico Montefusco; Maria Concetta Petti; A Zepparoni; Antonella Vitale; Robin Foa
Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission.
British journal of haematology 2001;113(1):136-42.
2000: Roberto Latagliata; Massimo Breccia; Alessandro Pulsoni; Maria Antonietta Aloe-Spiriti; Gianna Maria D'Elia; Antonio Spadea; Enrico Montefusco; Giuseppe Luzi; P Betrò; Maria Concetta Petti
Acute myeloblastic leukemia secondary to myelodysplasia (MDS-AML): a comparison of remission induction with three drugs versus standard two-drugs induction.
Leukemia & lymphoma 2000;36(5-6):539-41.
2000: Massimo Breccia; Maria Concetta Petti; G Fraternali Orcioni; Bruno Monarca; Roberto Latagliata; Gianna Maria D'Elia; Franco Mandelli; Stefano A Pileri
Granulocytic sarcoma with breast and skin presentation: a report of a case successfully treated by local radiation and systemic chemotherapy.
Acta haematologica 2000;104(1):34-7.
1999: Lidia De Felice; T Di Pucchio; Maria Grazia Mascolo; Francesca Agostini; Massimo Breccia; cesare guglielmi; Maria R Ricciardi; Agostino Tafuri; Maria Screnci; Franco Mandelli; William Arcese
Flt3LP3nduces the ex-vivo amplification of umbilical cord blood committed progenitors and early stem cells in short-term cultures.
British journal of haematology 1999;106(1):133-41.
1999: Corrado Girmenia; Roberto Latagliata; S Tosti; Susanna Morano; Francesca Celesti; L Coppola; Antonio Spadea; Massimo Breccia; R Battistini; Agostino Tafuri; Giuseppe Cimino; Franco Mandelli; Giuliana Alimena
Outpatient management of acute promyelocytic leukemia after consolidation chemotherapy.
Leukemia 1999;13(4):514-7.
1998: Lidia De Felice; T Di Pucchio; Massimo Breccia; Francesca Agostini; Maria Grazia Mascolo; cesare guglielmi; Maria R Ricciardi; Maria Screnci; Agostino Tafuri; D Carmini; William Arcese
Flt3L enhances the early stem cell compartment after ex vivo amplification of umbilical cord blood CD34+ cells.
Bone marrow transplantation 1998;22 Suppl 1():S66-7.
1997: Roberto Latagliata; Giuseppe Avvisati; Francesco Lo Coco; Maria Concetta Petti; Daniela Diverio; Antonio Spadea; Paola Fazi; Concetta Torromeo; Massimo Breccia; F Malagnino; Franco Mandelli
The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(12):1273-5.
1993: Francesco Lo Coco; Franco Mandelli; Massimo Breccia; Luciana Annino; cesare guglielmi; Maria Concetta Petti; Anna Maria Testi; Giuliana Alimena; C M Croce; E Canaani
Southern blot analysis of ALL-1 rearrangements at chromosome 11q23 in acute leukemia.
Cancer research 1993;53(16):3800-3.